These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 12352398

  • 1. Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery.
    Thalmann GN, Markwalder R, Walter B, Studer UE.
    J Urol; 2002 Oct; 168(4 Pt 1):1381-5. PubMed ID: 12352398
    [Abstract] [Full Text] [Related]

  • 2. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract.
    Hayashida Y, Nomata K, Noguchi M, Eguchi J, Koga S, Yamashita S, Hayashi M, Kanatake H.
    Urology; 2004 Jun; 63(6):1084-8. PubMed ID: 15183955
    [Abstract] [Full Text] [Related]

  • 3. [Percutaneous Bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ].
    Yamashita S, Yogi Y, Taniguchi K, Morimitsu H, Suzu H, Kanetake H, Saito Y, Kubota S.
    Hinyokika Kiyo; 1992 Oct; 38(10):1095-9. PubMed ID: 1481770
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G, Birkhäuser FD, Recker F, Thalmann GN, Studer UE.
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [Abstract] [Full Text] [Related]

  • 7. Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract.
    Nonomura N, Ono Y, Nozawa M, Fukui T, Harada Y, Nishimura K, Takaha N, Takahara S, Okuyama A.
    Eur Urol; 2000 Dec; 38(6):701-4;discussion 705. PubMed ID: 11111187
    [Abstract] [Full Text] [Related]

  • 8. Oncologic Outcomes Following Robot-Assisted Laparoscopic Nephroureterectomy with Bladder Cuff Excision for Upper Tract Urothelial Carcinoma.
    Aboumohamed AA, Krane LS, Hemal AK.
    J Urol; 2015 Dec; 194(6):1561-6. PubMed ID: 26192256
    [Abstract] [Full Text] [Related]

  • 9. The Expanded Use of Percutaneous Resection for Upper Tract Urothelial Carcinoma: A 30-Year Comprehensive Experience.
    Motamedinia P, Keheila M, Leavitt DA, Rastinehad AR, Okeke Z, Smith AD.
    J Endourol; 2016 Mar; 30(3):262-7. PubMed ID: 26630130
    [Abstract] [Full Text] [Related]

  • 10. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G, de Reijke TM, Prescott S, Witjes JA, Oosterlinck W.
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [Abstract] [Full Text] [Related]

  • 11. Biological Behavior and Long-Term Outcomes of Carcinoma In Situ in Upper Urinary Tract Managed by Radical Nephroureterectomy.
    Inamoto T, Matsuyama H, Ibuki N, Komura K, Takahara K, Fujimoto K, Shiina H, Sakano S, Nagao K, Miyake M, Tatsumi Y, Yasumoto H, Azuma H, Nishinihon Uro-Oncology Collaborative Group.
    J Urol; 2018 Apr; 199(4):933-939. PubMed ID: 29037861
    [Abstract] [Full Text] [Related]

  • 12. Outcomes of intrarenal Bacillus Calmette-Guérin/interferon-α2B for biopsy-proven upper-tract carcinoma in situ.
    Shapiro EY, Lipsky MJ, Cha DY, McKiernan JM, Benson MC, Gupta M.
    J Endourol; 2012 Dec; 26(12):1645-50. PubMed ID: 22834939
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma.
    Rink M, Robinson BD, Green DA, Cha EK, Hansen J, Comploj E, Margulis V, Raman JD, Ng CK, Remzi M, Bensalah K, Kabbani W, Haitel A, Rioux-Leclercq N, Guo CC, Chun FK, Kikuchi E, Kassouf W, Sircar K, Sun M, Sonpavde G, Lotan Y, Pycha A, Karakiewicz PI, Scherr DS, Shariat SF.
    J Urol; 2012 Aug; 188(2):398-404. PubMed ID: 22698626
    [Abstract] [Full Text] [Related]

  • 15. Long-term outcome of upper urinary tract carcinoma in situ: effectiveness of nephroureterectomy versus bacillus Calmette-Guérin therapy.
    Kojima Y, Tozawa K, Kawai N, Sasaki S, Hayashi Y, Kohri K.
    Int J Urol; 2006 Apr; 13(4):340-4. PubMed ID: 16734847
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovascular invasion after radical nephroureterectomy.
    Lee KS, Kim KH, Yoon YE, Choi KH, Yang SC, Han WK.
    Korean J Urol; 2015 Jan; 56(1):41-7. PubMed ID: 25598935
    [Abstract] [Full Text] [Related]

  • 20. Clinical outcome of bacillus Calmette-Guérin perfusion therapy for carcinoma in situ of the upper urinary tract.
    Miyake H, Eto H, Hara S, Okada H, Kamidono S, Hara I.
    Int J Urol; 2002 Dec; 9(12):677-80. PubMed ID: 12492951
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.